Back to top

Analyst Blog

Santarus, Inc recently announced that results from the CORE II clinical study were published in the journal Gut. The study, conducted in Europe, Australia, Israel and Russia, is one of the main phase III programs evaluating Uceris extended release tablet in patients suffering from active, mild to moderate ulcerative colitis.

Results showed that the 9 mg dose of Uceris had a statistically significant benefit over placebo in meeting the primary endpoint. The primary endpoint was the induction of combined clinical and endoscopic remission at week 8 in patients with active, mild to moderate ulcerative colitis.

Uceris 9 mg was found to be well tolerated by the patients. The adverse events observed in the Uceris 9 mg arm were similar to placebo. No important clinical differences were found between Uceris and placebo in relation to glucocorticoid-related symptoms.

We remind investors that on Jan 14, 2013, Uceris 9 mg received approval from the US Food and Drug Administration (FDA) for the induction of remission in patients with active, mild to moderate ulcerative colitis. The product was launched in the US in Feb 2013.

Santarus is focused on the commercialization of Uceris and is promoting the product to gastroenterologists, endocrinologists and other selected physicians.

We remind investors that companies like AstraZeneca (AZN - Analyst Report) and Salix Pharmaceuticals Ltd (SLXP - Analyst Report) have a presence in the ulcerative colitis market.

Santarus currently carries a Zacks Rank #3 (Hold). Meanwhile, Array BioPharma, Inc. (ARRY - Snapshot Report) looks well-positioned in the biopharma space. Array BioPharma carries a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%